# Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

> **NCT07053358** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 10 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **GENETIC:** LX111 Injection

## Key facts

- **NCT ID:** NCT07053358
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-02
- **Primary completion:** 2026-11-23
- **Final completion:** 2029-12-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07053358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07053358, "Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07053358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*